No quarterly revenue total was found in Filana Therapeutics, Inc.'s SEC filings.
Filana Therapeutics, Inc. (FLNA) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$6.1 million.
Revenue
—
Net income
$-10.73M
+0.7% vs year-ago quarter
Operating cash flow
$-6.09M
+2.0% vs year-ago quarter
Free cash flow
$-6.12M
+2.8% vs year-ago quarter
EPS
$-0.26
+54.8% vs year-ago quarter
Dividend per share
None
Shares outstanding
50.27M
+4.1% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- FLNA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Austin, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1069530
- Former names
- CASSAVA SCIENCES INC (until Feb 19, 2026); PAIN THERAPEUTICS INC (until Mar 25, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$11.3M | -$9.4M | -$11.2M | -$13.6M | -$11.9M |
| Net income | -$10.7M | -$8.6M | -$10.3M | -$12.5M | -$10.8M |
| Diluted EPS | — | — | — | -$0.26 | -$0.22 |
| Operating cash flow | -$6.1M | -$3.9M | -$8.9M | -$9.7M | -$6.2M |
| Free cash flow | -$6.1M | -$3.9M | — | -$10.2M | -$6.3M |
| Total assets | $100.1M | $103.9M | $108.4M | $118.4M | $129.7M |
| Total liabilities | $42.1M | $40.3M | $40.2M | $44.0M | $48.2M |
| Stockholders' equity | $58.0M | $63.6M | $68.1M | $74.4M | $81.6M |
| Cash and investments | $47.0M | $82.7M | $86.6M | $95.5M | $106.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Other events
|
Oct 20, 2026 | Oct 20, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 22, 2026 | Sep 22, 2026 |
| 8-K |
Current report
Listing notice
|
Sep 18, 2026 | Sep 17, 2026 |
| 10-Q | Quarterly report | Jul 29, 2026 | Jun 30, 2026 |
All 1002 Filana Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.